Literature DB >> 23400076

Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center.

Khalil Ghasemi Falavarjani1, Mehdi Modarres, Masih Hashemi, Mohammad M Parvaresh, Masood Naseripour, Abbas Zare-Moghaddam, Shahbaz Nekoozadeh.   

Abstract

PURPOSE: To assess the rate of infectious endophthalmitis in a single clinical center in Iran and to compare the rate of endophthalmitis in patients receiving postinjection antibiotics with those who did not.
METHODS: A retrospective chart review of patients who received intravitreal injections of bevacizumab was undertaken. Cases of clinical diagnoses of endophthalmitis were reviewed. Bevacizumab was obtained at the time of injection from a commercially available vial after aseptic cleansing of the rubber cover.
RESULTS: Five patients (six eyes) developed clinical endophthalmitis after the intravitreal bevacizumab injection. The risk per injection was 0.10% (6/5,901). One culture-positive case was found overall. Postinjection antibiotic drops were prescribed for 68% of eyes. All endophthalmitis cases were among those who received postoperative antibiotic eye drops. The difference in the rates of endophthalmitis between those receiving postinjection antibiotics and those who did not was not statistically significant (P = 0.18).
CONCLUSION: A low risk of endophthalmitis consistent with the range of previous studies was observed notwithstanding the usage of multiple use of a single vial. Postinjection antibiotic drops may not be necessary.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23400076     DOI: 10.1097/IAE.0b013e31826f0675

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  15 in total

1.  Antibiotic prophylaxis for preventing endophthalmitis after intravitreal injection: a systematic review.

Authors:  Francesca Menchini; Giacomo Toneatto; Alba Miele; Simone Donati; Paolo Lanzetta; Gianni Virgili
Journal:  Eye (Lond)       Date:  2018-06-11       Impact factor: 3.775

2.  Postoperative endophthalmitis incidence after intravitreal therapy: a comparison of two different preoperative antibiotic prophylaxis.

Authors:  Sergio Piscitello; Maria Vadalà
Journal:  Int Ophthalmol       Date:  2016-09-01       Impact factor: 2.031

3.  Risk of Infectious Endophthalmitis From a Resident-Performed Intravitreal Injection.

Authors:  H Russell Day; Janice C Law; Jennifer L Lindsey
Journal:  J Vitreoretin Dis       Date:  2020-12-10

4.  Endophthalmitis Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections.

Authors:  Stephen G Schwartz; Harry W Flynn
Journal:  Curr Ophthalmol Rep       Date:  2014-03-01

Review 5.  Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.

Authors:  K Ghasemi Falavarjani; Q D Nguyen
Journal:  Eye (Lond)       Date:  2013-05-31       Impact factor: 3.775

Review 6.  Ocular Infection: Endophthalmitis.

Authors:  Stephen G Schwartz; Harry W Flynn; Taraprasad Das; William F Mieler
Journal:  Dev Ophthalmol       Date:  2015-10-26

7.  Intravitreal administration of bevacizumab: pros and cons.

Authors:  Simin Dashti-Khavidaki; Mohammad Abdollahi
Journal:  Daru       Date:  2015-04-21       Impact factor: 3.117

8.  Endophthalmitis outbreak associated with repackaged bevacizumab.

Authors:  Laura S Edison; Hope O Dishman; Melissa J Tobin-D'Angelo; C Richard Allen; Alice Y Guh; Cherie L Drenzek
Journal:  Emerg Infect Dis       Date:  2015-01       Impact factor: 6.883

9.  Incidence of endophthalmitis following intravitreal Bevacizumab injection at a tertiary care hospital in Eastern Province of Saudi Arabia.

Authors:  Rizwan A Cheema; Ahmad M Alshihry; Haider R Cheema
Journal:  Saudi J Ophthalmol       Date:  2014-11-26

Review 10.  Neuroinflammatory responses in diabetic retinopathy.

Authors:  Ying Yu; Hui Chen; Shao Bo Su
Journal:  J Neuroinflammation       Date:  2015-08-07       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.